Jpmorgan Chase & Co »

Cartesian Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Cartesian Therapeutics (RNAC) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Cartesian Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Cartesian Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cartesian Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-09-30 $5.0M 309k 16.12
2024-06-30 $8.3M 306k 27.01

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Ser 1 S&p Common (SPY)
Meta Platforms Common (META)
Eli Lilly & Co Common (LLY)
Alphabet Common (GOOG)
Unitedhealth Group Common (UNH)
Mastercard Incorporated Common (MA)
Vanguard Index Fds S&p 500 Etf Common (VOO)
Ishares Core S&p 500 Etf Fund (IVV)
Vanguard Total Intl Bond Etf Fund (BNDX)
Broadcom Common (AVGO)
Exxon Mobil Corp Common (XOM)

View all positions for Jpmorgan Chase & Co

Top funds holding Cartesian Therapeutics

Siren
BlackRock
BlackRock
Citadel Advisors
Jpmorgan Chase & Co
MPM Oncology Impact Management
Vanguard Group
Dr. Jeffrey R. Jay, M.D.
Erste Asset Management GmbH
State Street Corporation
Geode Capital Management
Yale University
Logos Global Management
683 Capital Management
Northern Trust

View all funds holding Cartesian Therapeutics